anlotinib + teriprilumab

Anlotinib + teriprilumab is a combination therapy consisting of two investigational agents used in oncology. Anlotinib is a novel oral small molecule tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR1/2/3, FGFR1-4, PDGFRα/β, and c-Kit. It inhibits tumor growth primarily by blocking angiogenesis and cell proliferation pathways. Teriprilumab is a monoclonal antibody immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor on T cells; it enhances anti-tumor immunity by preventing PD-1-mediated inhibition of T-cell activity. The combination has been explored for synergistic effects in various cancers—most notably non-small cell lung cancer (NSCLC)—where it may overcome resistance to prior therapies such as EGFR inhibitors or chemotherapy. Both drugs are developed by Chinese pharmaceutical companies and have shown promising efficacy and manageable toxicity profiles in early clinical reports.